Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 1631928671 7161 716-
Enterprise Value (EV)1 33,968,65611 4691 5321 494
P/E ratio -3,87x-2,37x-10,5x-13,3x-11,2x-9,69x
Yield ------
Capitalization / Revenue 5,26x830x30,3x72,0x68,1x109x
EV / Revenue 1,10x297x19,6x61,6x60,7x95,2x
EV / EBITDA ---8,81x-10,9x-6,81x-5,70x
Price to Book ------
Nbr of stocks (in thousands) 24 18627 20643 01947 72847 728-
Reference price (USD) 6,737,0520,236,036,036,0
Announcement Date 03/12/201903/10/202003/10/2021---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 30,90,2328,623,825,215,7
EBITDA1 ---63,7-135-225-262
Operating profit (EBIT)1 -42,3-80,5-64,5-127-167-206
Operating Margin -137%-34 858%-225%-532%-663%-1 316%
Pre-Tax Profit (EBT)1 -39,7-77,9-64,8-128-185-217
Net income1 -38,9-77,2-66,2-127-167-206
Net margin -126%-33 414%-231%-533%-661%-1 312%
EPS2 -1,74-2,98-1,92-2,71-3,20-3,71
Dividend per Share ------
Announcement Date 03/12/201903/10/202003/10/2021---
1 USD in Million
2 USD
Previous periodNext period
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2
Net sales1 6,192,2710,35,0717,40,77
EBITDA1 -23,8-30,7-33,7-46,0--
Operating profit (EBIT)1 -24,0-30,9-33,9-38,0-30,0-48,2
Operating Margin -388%-1 363%-330%-749%-172%-6 291%
Pre-Tax Profit (EBT)1 -24,0-30,8-33,8-39,2-29,7-48,0
Net income1 -24,0-30,8-33,8-38,3-29,7-48,0
Net margin -388%-1 362%-329%-755%-171%-6 267%
EPS2 -0,54-0,69-0,70-0,77-0,72-1,02
Dividend per Share ------
Announcement Date 05/04/202108/04/202111/03/2021---
1 USD in Million
2 USD
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 ------
Net Cash position1 129123306248184223
Leverage (Debt / EBITDA) --4,80x1,84x0,82x0,85x
Free Cash Flow1 -50,4-42,4-73,0-86,0-127-164
ROE (Net Profit / Equities) ---36,8%-47,4%-78,2%-94,2%
Shareholders' equity1 --180268213218
ROA (Net Profit / Asset) ---27,6%-39,0%-60,3%-69,6%
Assets1 --240326277296
Book Value Per Share ------
Cash Flow per Share ------
Capex1 0,490,970,470,701,001,00
Capex / Sales 1,57%419%1,65%2,94%3,97%6,38%
Announcement Date 03/12/201903/10/202003/10/2021---
1 USD in Million
Previous periodNext period
Key data
Capitalization (USD) 1 716 307 042
Net sales (USD) 28 628 000
Number of employees 116
Sales / Employee (USD) 246 793
Free-Float 98,9%
Free-Float capitalization (USD) 1 696 693 343
Avg. Exchange 20 sessions (USD) 24 951 499
Average Daily Capital Traded 1,45%
EPS & Dividend